Jabbour SA, et al. - The researchers evaluated the effects of exenatide once weekly (QW) plus dapagliflozin, exenatide QW, or dapagliflozin added to metformin monotherapy on body weight, systolic blood pressure (SBP), and triglycerides in patients with type 2 diabetes mellitus (T2DM). Across baseline subgroups, the combination of exenatide QW plus dapagliflozin reduced cardiovascular risk factors for each variable to a greater extent than either individual drug. The greatest effects were noted for body weight and SBP in the high baseline subgroups.